Micro-Abstractv-Raf murine sarcoma viral oncogene homolog B (BRAF)-mutated (MT) metastatic colorectal cancer (mCRC) has a poor prognosis. We report real-world data on treatment and survival of these patients, compared with an age and sex-matched control group. We found that progression-free survival is poor after first-line progression. Recruitment to clinical trials is recommended to improve outcomes in BRAF-MT mCRC.
Clinical Colorectal Cancer – Elsevier
Published: Mar 1, 2018
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.
All for just $49/month
It’s easy to organize your research with our built-in tools.
All the latest content is available, no embargo periods.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud